A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma
NCT03339219
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
35
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Renal Cell Carcinoma
Interventions
DRUG:
Cabozantinib
Sponsor
Takeda